论文部分内容阅读
目的观察尿激酶溶栓治疗急性心肌梗死（ＡＭＩ）的疗效及血液流变学中的纤维蛋白原、红细胞压积、血沉的变化、方法 按ＷＨＯ诊断ＡＭＩ的标准选择病例，采用１９９２年全国统一的溶栓方案治疗，同时检测溶栓前后血液流变学中的红细胞压积、纤维蛋白原、血沉等指标，并与溶栓结果对比分析。结果溶栓后ＡＭＩ患者再通车７８．６％；患者的纤维蛋白原、红细胞压积及血沉等明显低于溶栓前，统计学处理差异非常显著，Ｐ＜０．００１。结论ＡＭＩ患者存在血液流变学障碍，尿激酶可以改善血流变学异常，尿激酶溶栓治疗对ＡＭＩ效果肯定。
Objective To observe the curative effect of urokinase thrombolytic therapy on acute myocardial infarction (AMI) and changes of fibrinogen, hematocrit and erythrocyte sedimentation rate in hemorheology.Methods According to the WHO criteria of selecting AMI for diagnosis, Thrombolytic therapy, thrombolysis at the same time hemodialysis hematological hematocrit, fibrinogen, erythrocyte sedimentation rate and other indicators, and thrombolytic results were analyzed. Results After thrombolysis AMI patients reopened 78.6%; fibrinogen, hematocrit and ESR in patients were significantly lower than before thrombolysis, the statistical difference was significant (P <0.001). Conclusion There are hemorheological disorders in patients with AMI, urokinase can improve hemorrheology, urokinase thrombolytic therapy for AMI affirmed.